Burkhard F. Leeb
Research Subjects
Burkhard F. Leeb has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Bernhard Rintelen
Lower Austrian Center for Rheumatology, State Hospital Stockerau, Stockerau, Austria
6 shared publicationsJudith Sautner
Lower Austrian Center for Rheumatology, State Hospital Stockerau, Stockerau, Austria
5 shared publicationsChristian Fassl
Lower Austrian Center for Rheumatology, State Hospital Stockerau, Stockerau, Austria
3 shared publicationsIngrid Andel
HUMANIS Klinikum Lower Austria, Lower Austrian Center for Rheumatology, Karl Landsteiner-Institute for Clinical Rheumatology, Stockerau, Austria
3 shared publicationsB. Rintelen
NÖ Zentrum für Rheumatologie, Landesklinikum Weinviertel Stockerau, Karl Landsteiner Institut für Klinische Rheumatologie
2 shared publicationsJ. Sautner
Second Department of Medicine, Humanisklinikum Lower Austria, Lower Austrian Centre for Rheumatology, Stockerau, Austria
2 shared publications
Latest Publications
- 22 September 2007
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 66 (7) , 568-572
Evidenzbasierte Empfehlungen der „European League Against Rheumatism“ zur Diagnostik und Therapie der Gicht
- 22 September 2007
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 66 (7) , 568-572
Evidenzbasierte Empfehlungen der „European League Against Rheumatism“ zur Diagnostik und Therapie der Gicht
- Open Access
- 25 May 2007
- Published by Wiley in Arthritis Care & Research
- Vol. 57 (5) , 810-815
The polymyalgia rheumatica activity score in daily use: Proposal for a definition of remission
Objective: To confirm the reliability and applicability of the Polymyalgia Rheumatica Disease Activity Score (PMR‐AS), and to establish a threshold for remission.Methods: First, 78 patients with PMR (50 women/28 men, mean age 65.97 years) were enrolled in a cross‐sectional evaluation. The PMR‐AS, patient's satisfaction with disease status (PATSAT; range 1–5), erythrocyte sedimentation rate (ESR; first hour), and a visual analog scale of patients' general health assessment (VAS patient global; range 0–100) were recorded. Subsequently, another 39 PMR patients (24 women/15 men, mean age 68.12 years) were followed longitudinally. Relationships between the PMR‐AS, PATSAT, ESR, and VAS patient global were analyzed by the Kruskal‐Wallis test, Spearman's rank correlation, and kappa statistics. PMR‐AS values in patients with a PATSAT score of 1 and a VAS patient global P < 0.001), VAS patient global (P < 0.001), and ESR (P < 0.01). PATSAT and VAS patient global were reasonably different (κ = 0.226). The median PMR‐AS score in patients with PATSAT score 1 and VAS patient global <10 was 0.7 (range 0–3.3), and the respective 75th percentile was 1.3. To enhance applicability, a range from 0 to 1.5 was proposed to define remission in PMR. The median ESR in these patients was 10 mm/hour (range 3–28), indicating external validity.Conclusion: We demonstrated the reliability, validity, and applicability of the PMR‐AS in daily routine. Moreover, we proposed a remission threshold (0–1.5) founded on patient‐dependent parameters.
- 25 May 2007
- Published by Wiley in Arthritis Care & Research
- Vol. 57 (5) , 810-815
Open AccessThe polymyalgia rheumatica activity score in daily use: Proposal for a definition of remission
Objective: To confirm the reliability and applicability of the Polymyalgia Rheumatica Disease Activity Score (PMR‐AS), and to establish a threshold for remission.Methods: First, 78 patients with PMR (50 women/28 men, mean age 65.97 years) were enrolled in a cross‐sectional evaluation. The PMR‐AS, patient's satisfaction with disease status (PATSAT; range 1–5), erythrocyte sedimentation rate (ESR; first hour), and a visual analog scale of patients' general health assessment (VAS patient global; range 0–100) were recorded. Subsequently, another 39 PMR patients (24 women/15 men, mean age 68.12 years) were followed longitudinally. Relationships between the PMR‐AS, PATSAT, ESR, and VAS patient global were analyzed by the Kruskal‐Wallis test, Spearman's rank correlation, and kappa statistics. PMR‐AS values in patients with a PATSAT score of 1 and a VAS patient global P < 0.001), VAS patient global (P < 0.001), and ESR (P < 0.01). PATSAT and VAS patient global were reasonably different (κ = 0.226). The median PMR‐AS score in patients with PATSAT score 1 and VAS patient global <10 was 0.7 (range 0–3.3), and the respective 75th percentile was 1.3. To enhance applicability, a range from 0 to 1.5 was proposed to define remission in PMR. The median ESR in these patients was 10 mm/hour (range 3–28), indicating external validity.Conclusion: We demonstrated the reliability, validity, and applicability of the PMR‐AS in daily routine. Moreover, we proposed a remission threshold (0–1.5) founded on patient‐dependent parameters.
- Open Access
- 28 February 2007
- Published by Wiley in Arthritis Care & Research
- Vol. 57 (2) , 256-260
The Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients
Objective: To assess the factorial structure of the Disease Activity Score including a 28‐joint count (DAS28) if applied in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).Methods: DAS28 values from 85 consecutive PsA outpatients and 2 RA patient cohorts comprising 85 patients each were compared. The first RA cohort (RA1) consisted of age‐ and sex‐matched patients seen during the same period as the patients with PsA. The first 85 RA outpatients from September 2003 were included in the second cohort (RA2). Item weighting, factor loading, and internal consistency were assessed by factor analysis, principal component analysis, and calculation of Cronbach's alpha.Results: The mean ± SD DAS28 scores of patients in the PsA, RA1, and RA2 cohorts were 3.2 ± 1.31, 3.21 ± 1.45, and 3.79 ± 1.44, respectively. A significant difference between the PsA and RA2 cohorts was found for DAS28 (P = 0.0063), swollen joint count (P = 0.007), and patient's global assessment (P < 0.001), but not for erythrocyte sedimentation rate. Internal consistency of the DAS28 in patients with PsA was considerably lower, item weighting showed remarkable differences, and factor analysis revealed that the DAS28 constitutes a bidimensional instrument in patients with PsA, whereas in both RA cohorts it appeared to be monodimensional.Conclusion: With respect to its statistical properties, the DAS28 proved to be considerably different in PsA compared with RA. Therefore its application for disease activity assessment in patients with PsA cannot be recommended without a formal validation procedure.
- 28 February 2007
- Published by Wiley in Arthritis Care & Research
- Vol. 57 (2) , 256-260
Open AccessThe Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients
Objective: To assess the factorial structure of the Disease Activity Score including a 28‐joint count (DAS28) if applied in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).Methods: DAS28 values from 85 consecutive PsA outpatients and 2 RA patient cohorts comprising 85 patients each were compared. The first RA cohort (RA1) consisted of age‐ and sex‐matched patients seen during the same period as the patients with PsA. The first 85 RA outpatients from September 2003 were included in the second cohort (RA2). Item weighting, factor loading, and internal consistency were assessed by factor analysis, principal component analysis, and calculation of Cronbach's alpha.Results: The mean ± SD DAS28 scores of patients in the PsA, RA1, and RA2 cohorts were 3.2 ± 1.31, 3.21 ± 1.45, and 3.79 ± 1.44, respectively. A significant difference between the PsA and RA2 cohorts was found for DAS28 (P = 0.0063), swollen joint count (P = 0.007), and patient's global assessment (P < 0.001), but not for erythrocyte sedimentation rate. Internal consistency of the DAS28 in patients with PsA was considerably lower, item weighting showed remarkable differences, and factor analysis revealed that the DAS28 constitutes a bidimensional instrument in patients with PsA, whereas in both RA cohorts it appeared to be monodimensional.Conclusion: With respect to its statistical properties, the DAS28 proved to be considerably different in PsA compared with RA. Therefore its application for disease activity assessment in patients with PsA cannot be recommended without a formal validation procedure.
- Open Access
- 25 September 2006
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 166 (17) , 1899-1906
A Meta-analysis of Controlled Clinical Studies With Diacerein in the Treatment of Osteoarthritis
Osteoarthritis is the most common affliction of synovial joints in Western populations,1 with the large, weight-bearing joints such as the hip and the knee being the most affected. Clinical manifestations comprise fluctuating joint pain, swelling, stiffness, and loss of motion. The main objectives in the management of osteoarthritis are to reduce symptoms and improve functionality. Another major objective is to reduce or even halt the progression of structural changes and, thereby, to delay or even avoid the need for prostheses.
- 25 September 2006
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 166 (17) , 1899-1906
Open AccessA Meta-analysis of Controlled Clinical Studies With Diacerein in the Treatment of Osteoarthritis
Osteoarthritis is the most common affliction of synovial joints in Western populations,1 with the large, weight-bearing joints such as the hip and the knee being the most affected. Clinical manifestations comprise fluctuating joint pain, swelling, stiffness, and loss of motion. The main objectives in the management of osteoarthritis are to reduce symptoms and improve functionality. Another major objective is to reduce or even halt the progression of structural changes and, thereby, to delay or even avoid the need for prostheses.
- 4 January 2006
- Published by Springer Nature in Clinical Rheumatology
- Vol. 25 (4) , 557-559
Leflunomide/chloroquin combination therapy in rheumatoid arthritis: a pilot study
The objective of this study was to assess the efficacy and tolerability of a combination of leflunomide (LEF) and chloroquin (ChL) in patients with rheumatoid arthritis (RA). Fifteen female RA patients (46–80 years, mean disease duration 100.7 months, ten patients RF+) were enrolled into this open trial. Patients were either treatment failures or partial responders to LEF (n=6) or ChL (n=9). At week 8 and 16, DAS28 and morning stiffness (MST) were evaluated. Moreover, safety was assessed by reporting of side effects, laboratory examinations, and blood pressure measurement. Baseline mean disease activity Index including a 28-joint count (DAS28) amounted to 5.61 and decreased to 4.54 at week 8 (p=0.023) and to 3.79 (p=0.00031) at week 16. MST remained unchanged. DAS28 values significantly decreased statistically in originally ChL-treated patients with additional LEF but did not in LEF patients with additional ChL (DAS28: 1.48; 2.29 vs 0.60; 0.87). Adverse reactions were observed in four patients. Three patients had to be withdrawn from the study. Combination therapy with LEF and ChL was effective and reasonably tolerated. The far higher treatment response could be observed in originally ChL-treated patients after initiation of LEF.
- 4 January 2006
- Published by Springer Nature in Clinical Rheumatology
- Vol. 25 (4) , 557-559
Leflunomide/chloroquin combination therapy in rheumatoid arthritis: a pilot study
The objective of this study was to assess the efficacy and tolerability of a combination of leflunomide (LEF) and chloroquin (ChL) in patients with rheumatoid arthritis (RA). Fifteen female RA patients (46–80 years, mean disease duration 100.7 months, ten patients RF+) were enrolled into this open trial. Patients were either treatment failures or partial responders to LEF (n=6) or ChL (n=9). At week 8 and 16, DAS28 and morning stiffness (MST) were evaluated. Moreover, safety was assessed by reporting of side effects, laboratory examinations, and blood pressure measurement. Baseline mean disease activity Index including a 28-joint count (DAS28) amounted to 5.61 and decreased to 4.54 at week 8 (p=0.023) and to 3.79 (p=0.00031) at week 16. MST remained unchanged. DAS28 values significantly decreased statistically in originally ChL-treated patients with additional LEF but did not in LEF patients with additional ChL (DAS28: 1.48; 2.29 vs 0.60; 0.87). Adverse reactions were observed in four patients. Three patients had to be withdrawn from the study. Combination therapy with LEF and ChL was effective and reasonably tolerated. The far higher treatment response could be observed in originally ChL-treated patients after initiation of LEF.
Intravenous application of omega‐3 fatty acids in patients with active rheumatoid arthritis. The ORA‐1 trial. An open pilot study
The objective of this work was to assess the therapeutic efficacy and to lerability of intravenously applied n‐3‐PUFA in patients with active rheumatoid arthritis (RA). Thirty‐four patients with active RA [identified as having a DAS28 (disease activity score including a 28 joint count) >4.0] were enrolled into this 5‐wk open pilot study (one group design). From the time of screening (visit 0, or V0), background therapy had to remain unchanged. Patients received 2 mL/kg(=0.1–0.2 g fish oil/kg) fish oil emulsion intravenously on 7 consecutive days (Visit 1–Visit 2, or V1–V2) in addition to their background therapy. A decrease of the DAS28>0.6 at day 8 (Visit 2) was the primary efficacy measure. Moreover, the DAS28 at day 35 (Visit 3, or V3), the modified Health Assessment Questionnaire, the American College of Rheumatology (ACR) response criteria (V2, V3) and the Short Form‐36 (V3) were assessed. Thirty‐three patients completed the trial. The mean DAS28 at V1 was 5.45; at V2, 4.51 (P<.001 V1–V2) and at V3, 4.73 (P<.001 V1–V3; V2–V3, not significantly different). Of the 34 patients, 56% achieved a reduction of the DAS28>0.6 at V2 (mean 1.52); 27%>1.2. At V3, 41% of the patients showed a DAS28 reduction >0.6 (mean 1.06), and 36%>1.2. ACR 20 and 50% responses at V2 were seen in 29 and 12% of patients, respectively; at V3, the comparable values were 18 and 9%, respectively. Overall tolerability was excellent. Intravenous application of n‐3‐PUFA (as an add‐on therapy) was considerably well tolerated and led to improvement of the disease activity status in a reasonable number of RA patients. Future trials are warranted to answer whether the intravenous application of n‐3‐PUFA constitutes a therapeutic option in RA patients.
Intravenous application of omega‐3 fatty acids in patients with active rheumatoid arthritis. The ORA‐1 trial. An open pilot study
The objective of this work was to assess the therapeutic efficacy and to lerability of intravenously applied n‐3‐PUFA in patients with active rheumatoid arthritis (RA). Thirty‐four patients with active RA [identified as having a DAS28 (disease activity score including a 28 joint count) >4.0] were enrolled into this 5‐wk open pilot study (one group design). From the time of screening (visit 0, or V0), background therapy had to remain unchanged. Patients received 2 mL/kg(=0.1–0.2 g fish oil/kg) fish oil emulsion intravenously on 7 consecutive days (Visit 1–Visit 2, or V1–V2) in addition to their background therapy. A decrease of the DAS28>0.6 at day 8 (Visit 2) was the primary efficacy measure. Moreover, the DAS28 at day 35 (Visit 3, or V3), the modified Health Assessment Questionnaire, the American College of Rheumatology (ACR) response criteria (V2, V3) and the Short Form‐36 (V3) were assessed. Thirty‐three patients completed the trial. The mean DAS28 at V1 was 5.45; at V2, 4.51 (P<.001 V1–V2) and at V3, 4.73 (P<.001 V1–V3; V2–V3, not significantly different). Of the 34 patients, 56% achieved a reduction of the DAS28>0.6 at V2 (mean 1.52); 27%>1.2. At V3, 41% of the patients showed a DAS28 reduction >0.6 (mean 1.06), and 36%>1.2. ACR 20 and 50% responses at V2 were seen in 29 and 12% of patients, respectively; at V3, the comparable values were 18 and 9%, respectively. Overall tolerability was excellent. Intravenous application of n‐3‐PUFA (as an add‐on therapy) was considerably well tolerated and led to improvement of the disease activity status in a reasonable number of RA patients. Future trials are warranted to answer whether the intravenous application of n‐3‐PUFA constitutes a therapeutic option in RA patients.
- 1 January 2006
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 35 (6) , 441-446
Lack of agreement between patients' and physicians' perspectives of rheumatoid arthritis disease activity changes
Objective: To obtain information on changes in patients' satisfaction (PATSAT) and physicians' global assessment (PhGASS) with regard to rheumatoid arthritis (RA) activity fluctuations. Methods: Eighty‐eight RA outpatients out of 207 investigated were assessed for 3 months on average after the initial evaluation. PATSAT (1 = excellent to 5 = unsatisfactory), PhGASS (visual analogue scale 1–100), and the 28‐joint Disease Activity Score (DAS28) were assessed as at the first evaluation. The only prerequisite for enrolment was any therapeutic change at the first visit. Changes in PATSAT (SATCH) and PhGASS (PhGACH) were categorized and subsequently related to the DAS28 changes. Statistical evaluation was carried out by the Kruskal–Wallis test, the Mann–Whitney U‐test, and by kappa statistics. Results: To achieve a positive SATCH (n = 26/88 patients), a median DAS28 reduction of −1.06 (−25.0%) was necessary, whereas a considerably lower median increase of +0.16 (+10.5%) caused a negative SATCH. PhGASS (n = 38/88 patients) changed positively on a median DAS28 reduction of −0.82 (−16.0%), whereas it worsened at a mean DAS28 increase of +0.55 (+16.5%). Approximately 60% congruence between SATCH and PhGACH could be observed (kappa = 0.139). The DAS28 values preceding a positive SATCH and PhGACH were significantly higher (p<0.001) than before a negative change. Conclusion: The patients' perspective with respect to improvement or worsening of RA is asymmetric. In contrast to the physicians' perspective, patients require greater improvement to be satisfied and less deterioration to be dissatisfied. These results may provide additional guidance in considerations about defining response and non‐response in RA.
- 1 January 2006
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 35 (6) , 441-446
Lack of agreement between patients' and physicians' perspectives of rheumatoid arthritis disease activity changes
Objective: To obtain information on changes in patients' satisfaction (PATSAT) and physicians' global assessment (PhGASS) with regard to rheumatoid arthritis (RA) activity fluctuations. Methods: Eighty‐eight RA outpatients out of 207 investigated were assessed for 3 months on average after the initial evaluation. PATSAT (1 = excellent to 5 = unsatisfactory), PhGASS (visual analogue scale 1–100), and the 28‐joint Disease Activity Score (DAS28) were assessed as at the first evaluation. The only prerequisite for enrolment was any therapeutic change at the first visit. Changes in PATSAT (SATCH) and PhGASS (PhGACH) were categorized and subsequently related to the DAS28 changes. Statistical evaluation was carried out by the Kruskal–Wallis test, the Mann–Whitney U‐test, and by kappa statistics. Results: To achieve a positive SATCH (n = 26/88 patients), a median DAS28 reduction of −1.06 (−25.0%) was necessary, whereas a considerably lower median increase of +0.16 (+10.5%) caused a negative SATCH. PhGASS (n = 38/88 patients) changed positively on a median DAS28 reduction of −0.82 (−16.0%), whereas it worsened at a mean DAS28 increase of +0.55 (+16.5%). Approximately 60% congruence between SATCH and PhGACH could be observed (kappa = 0.139). The DAS28 values preceding a positive SATCH and PhGACH were significantly higher (p<0.001) than before a negative change. Conclusion: The patients' perspective with respect to improvement or worsening of RA is asymmetric. In contrast to the physicians' perspective, patients require greater improvement to be satisfied and less deterioration to be dissatisfied. These results may provide additional guidance in considerations about defining response and non‐response in RA.
- 1 January 2006
- Published by Springer Nature in Drugs & Aging
- Vol. 23 (5) , 391-402
Diagnosis, Differential Diagnosis and Treatment of Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is a common disorder in the elderly population. The diagnosis is based upon recognition of a clinical syndrome, consisting of pain and stiffness in the shoulder and pelvic girdle, muscle tenderness of the upper and lower limbs and nonspecific somatic complaints. In addition, in most cases the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) concentration are highly elevated. Although PMR and giant cell arteritis (GCA) are commonly regarded as two clinical variations of the same disease, their clinical picture is quite different. Whilst in PMR the musculoskeletal symptoms predominate, the major features of GCA are arterial inflammation and its consequences, which suggests clinical and pathological discrepancies between the two syndromes and important differences with respect to morbidity and mortality. The prognosis of correctly diagnosed PMR is excellent. It is well known that corticosteroid therapy in PMR usually leads to rapid and dramatic improvement of patients’ complaints and returns them to previous functional status. However, prolonged corticosteroid treatment, sometimes for several years, may be necessary to maintain clinical improvement. Despite all the knowledge about the beneficial effects of corticosteroid treatment, data concerning the optimal dosage regimen are lacking. Long-term corticosteroid use can be associated with various adverse events, of which induction of osteoporosis, diabetes mellitus and infection among the worst. A Corticosteroid Side Effect Questionnaire has been shown to dose-dependently detect adverse effects perceived by patients. The European League Against Rheumatism (EULAR) response criteria for PMR comprise a core set of markers for monitoring therapeutic responses in PMR, namely ESR or CRP, the visual analogue scale of patient’s pain and physician’s global assessment, as well as morning stiffness and the ability to elevate the upper limbs. The PMR-disease activity score has been developed on the basis of EULAR response criteria as a means of expressing disease activity as an absolute number. A score 17 is indicative of high disease activity. The PMR-disease activity score has been proven to be highly correlated with patient’s global assessment, patient satisfaction and ESR. It provides an easily applicable and valid tool for disease activity monitoring in patients with PMR. Improved knowledge of disease activity processes, exact monitoring of disease activity and treatment responses, and increased risk-estimation of treatment schedules should ultimately improve the care of patients with PMR.
- 1 January 2006
- Published by Springer Nature in Drugs & Aging
- Vol. 23 (5) , 391-402
Diagnosis, Differential Diagnosis and Treatment of Polymyalgia Rheumatica
Polymyalgia rheumatica (PMR) is a common disorder in the elderly population. The diagnosis is based upon recognition of a clinical syndrome, consisting of pain and stiffness in the shoulder and pelvic girdle, muscle tenderness of the upper and lower limbs and nonspecific somatic complaints. In addition, in most cases the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) concentration are highly elevated. Although PMR and giant cell arteritis (GCA) are commonly regarded as two clinical variations of the same disease, their clinical picture is quite different. Whilst in PMR the musculoskeletal symptoms predominate, the major features of GCA are arterial inflammation and its consequences, which suggests clinical and pathological discrepancies between the two syndromes and important differences with respect to morbidity and mortality. The prognosis of correctly diagnosed PMR is excellent. It is well known that corticosteroid therapy in PMR usually leads to rapid and dramatic improvement of patients’ complaints and returns them to previous functional status. However, prolonged corticosteroid treatment, sometimes for several years, may be necessary to maintain clinical improvement. Despite all the knowledge about the beneficial effects of corticosteroid treatment, data concerning the optimal dosage regimen are lacking. Long-term corticosteroid use can be associated with various adverse events, of which induction of osteoporosis, diabetes mellitus and infection among the worst. A Corticosteroid Side Effect Questionnaire has been shown to dose-dependently detect adverse effects perceived by patients. The European League Against Rheumatism (EULAR) response criteria for PMR comprise a core set of markers for monitoring therapeutic responses in PMR, namely ESR or CRP, the visual analogue scale of patient’s pain and physician’s global assessment, as well as morning stiffness and the ability to elevate the upper limbs. The PMR-disease activity score has been developed on the basis of EULAR response criteria as a means of expressing disease activity as an absolute number. A score 17 is indicative of high disease activity. The PMR-disease activity score has been proven to be highly correlated with patient’s global assessment, patient satisfaction and ESR. It provides an easily applicable and valid tool for disease activity monitoring in patients with PMR. Improved knowledge of disease activity processes, exact monitoring of disease activity and treatment responses, and increased risk-estimation of treatment schedules should ultimately improve the care of patients with PMR.
- 1 December 2005
- Published by Springer Nature in Die Innere Medizin
- Vol. 46 (12) , 1399-1404
Moderne antirheumatische Pharmakotherapie
- 1 December 2005
- Published by Springer Nature in Die Innere Medizin
- Vol. 46 (12) , 1399-1404
Moderne antirheumatische Pharmakotherapie
- 12 October 2005
- Published by Springer Nature in Clinical Rheumatology
- Vol. 25 (4) , 577-578
Intravenous application of omega-3 fatty acids in a patient with active spondylarthropathy—a case report
- 12 October 2005
- Published by Springer Nature in Clinical Rheumatology
- Vol. 25 (4) , 577-578
Intravenous application of omega-3 fatty acids in a patient with active spondylarthropathy—a case report